title: [Gemfibrozil in the treatment of hyperlipoproteinemia].
abstract: Within the framework of clinical tests of the preparation Gevilon (gemfibrosil tablets 450 mg) of Parke-Davis Co. this hypolipidaemic preparation was administered to 28 patients with different types of hyperlipoproteinaemia. One-month administration of gemfibrosil, 900 mg per day, significantly influenced some parameters of the lipid and lipoprotein metabolism. Plasma cholesterol declined by 20%, triglycerides by as much as 60%. On the other hand, the HDL cholesterol level did not change. The concentration of the "risk" apolipoprotein B declined by 11%, that of apolipoprotein A1 which is considered protective from the aspect of ischaemic heart disease increased by 21%. There is a significant decline of lipoprotein Lp(a) which was not described in hypolipidaemic drugs of the clofibrate type. Treatment with Gevilon led also to a marked decline of the serum uric acid level. Gemfibrisol is according to the authors' experience as well as according to the results of other authors an effective hypolipidaemic agent suitable for the majority of patients with hyperlipoproteinaemia. Treatment with gemfibrosil leads to a significant decline of the prevalence of ischaemic heart disease.
authors.forename: R
authors.initials: R
authors.lastname: Ceska
authors.forename: J
authors.initials: J
authors.lastname: Sobra
mesh_terms: D000293:Adolescent; D000328:Adult; D005260:Female; D015248:Gemfibrozil / Q000627:therapeutic use*; D006801:Humans; D006951:Hyperlipoproteinemias / Q000097:blood / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged
chemical_list: D008055:Lipids; D008074:Lipoproteins; D015248:Gemfibrozil
vernacular_title: Gemfibrozil v lécbĕ hyperlipoproteinémií.